The contribution of periodontitis to the inflammatory burden in rheumatoid arthritis

Coimbra Rheumatology Association (ARCo)0 个研究点目标入组 22 人开始时间: 2019年11月14日最近更新: 2024年7月29日

适应症

试验速览

2024 Results article in https://pubmed.ncbi.nlm.nih.gov/39002123/ (added 16/07/2024)

•1. 18-70 years old
•2. RA diagnosis according to ACR/EULAR 2010 criteria
•3. Capable of understanding the study protocol and willing to provide informed consent for clinical evaluation.
•4. DAS28 PCR = 3,1 (with no change in medication, dose, or formulation in RA treatment during the 3 months preceding Phase 1 periodontal evaluation and 32 weeks after)
•5. Presence of at least six natural teeth
•6. Moderate to Severe CP diagnosis (Clinical Attachment Level > 3mm)
•7. Available for all study visits over 32 weeks

•1. Pregnant or breastfeeding
•2. Smoking habits (past or current)
•4. Chronic respiratory disease that could lead to a present state of respiratory insufficiency
•5. Presence of other conditions associated with increased CRP, namely:
•5.1. Other inflammatory rheumatic diseases other than RA.
•5.2. Other active inflammatory diseases (IBD, chronic infections, etc.)
•5.3. Current/actual neoplastic diagnosis/treatment
•6. History of infection/ antibiotic therapy within the preceding 4 weeks
•7. History of periodontal therapy 6 months prior to the examination;
•8. Planned hospitalization for pre-existing condition apart from RA within 32 weeks after Phase 1 periodontal evaluation
•9. Hypersensitivity to chlorhexidine digluconate.
•10. Contraindications to dental local anesthetic.
•11. Current and past (last 6 months) participation in another intervention study

发起方

Coimbra Rheumatology Association (ARCo)